Gene knockout in cellular immunotherapy: Application and limitations. (1st August 2022)

• Record Type: Journal Article
• Authors: Zhang, Xiaomei; Jin, Xin; Sun, Rui; Zhang, Meng; Lu, Wenyi; Zhao, Mingfeng
• Is Part Of: Cancer letters. Volume 540(2022)
• Publication Date: 2022-08-01
• Subjects: Gene editing -- RNA interference -- Genetic engineering -- Immunotherapy -- Gene delivery; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2022.215736
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Cellular immunotherapy has achieved incremental success in recent years. Varieties of cell products are undergoing fundamental research and clinical trials, among which CAR-T cell therapy is approved for marketing. As research progresses, these cells need to be modified to promote their safety and efficacy. Gene-editing technologies have evolved from RNA interference (RNAi), including small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs), to new generations of zinc finger nucleases (ZFNs), transcription-activator-like effector nucleases (TALENs), and clusters of regularly spaced short palindromic repeats (CRISPR/Cas9), and delivery methods are widely used. Here, we summarize the ongoing clinical trials and fundamental research for genome editing therapy. Additionally, we highlight existing in vivo delivery systems and their limitations to find a better method to deliver genes. Highlights: Gene editing techniques knockdown or knockout certain genes on engineered cells. In vivo delivery of gene editing technology was realized by different delivery methods. Cellular immunotherapy can be better realized by combining gene knockout methods with delivery forms.